Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2020-10-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
独立董事关于第四届董事会第十六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on specific matters discussed at the company's fourth board of directors' sixteenth meeting. It references compliance with regulatory guidelines and provides independent opinions on cash management and guarantees for subsidiaries. The document is short (1048 characters) and does not contain financial statements or detailed financial data. It is a formal opinion related to board meeting matters rather than a full report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management activities.
2020-10-29 Chinese
2020年第三季度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (370 characters) stating that the company's 2020 third quarter report will be published on a specific date and website. It does not contain the actual financial data or report itself, but only informs investors about the upcoming release. According to the 'MENU VS MEAL' rule, such a brief notice about report publication is classified as a Report Publication Announcement (RPA).
2020-10-29 Chinese
东莞证券股份有限公司关于公司子公司使用暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent financial advisor's opinion on the use of temporarily idle raised funds by a subsidiary of the company for cash management purposes. It references regulatory requirements such as the China Securities Regulatory Commission approvals, Shenzhen Stock Exchange rules, and relevant laws governing the management and use of raised funds. The document includes specifics about the raised funds, their storage, usage, investment risk, risk control measures, and approvals by the board and supervisory committees. It is not a full annual or interim financial report, nor an earnings release or a simple announcement. It is a formal audit or verification opinion related to the use of raised funds, which fits the category of an Audit Report / Information (AR). The document length (5412 characters) and content confirm it is a substantive report, not just an announcement or certification letter, so it is not RPA or RNS. Q4 2020
2020-10-29 Chinese
关于子公司使用暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 福安药业（集团）股份有限公司 regarding the use of temporarily idle raised funds by a subsidiary for cash management. It details the approval by the board, the amount involved (up to 30 million RMB), the purpose, risk controls, and compliance with regulatory requirements. The document references regulatory guidelines and approvals related to the use of raised funds but does not contain financial statements or comprehensive financial data. It is a formal disclosure about a financing/capital management activity rather than a full financial report or earnings release. The document length is 4512 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2020-10-29 Chinese
第四届监事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 13th meeting of the 4th Supervisory Board of the company 福安药业（集团）股份有限公司, held on October 29, 2020. It includes voting results on several agenda items such as approval of the 2020 Q3 report, cash management plans, and guarantees for bank financing. The document is short (1040 characters) and primarily serves as a meeting resolution announcement rather than the full quarterly report itself. It does not contain detailed financial statements or substantive financial data, but rather the supervisory board's approval and opinions on these matters. Therefore, it is not an Interim/Quarterly Report (IR) but an official announcement of board/management decisions. This fits best under Board/Management Information (MANG).
2020-10-29 Chinese
2020年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "福安药业（集团）股份有限公司 2020 年第三季度报告全文" which translates to "Fuan Pharmaceutical (Group) Co., Ltd. 2020 Third Quarter Report Full Text." It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and notes on financial metrics for the third quarter of 2020. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly) confirms this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2020
2020-10-29 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.